Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01848821 · ClinicalTrials.gov registry record · Phase 1
The Effect of OASIS Ultra on Critical Sized Wound Healing
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT01848821: Completed Phase 1 study, sponsored by Massachusetts General Hospital.
NCT01848821 is a Phase 1 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 7 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01848821, a Phase 1 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The aim of this study is to evaluate the speed and quality with which OASIS® Ultra (Healthpoint Biotherapeutics; Fort Worth, Texas) increases wound healing in the critical sized defect. The investigators intend on confirming the histological composition of the dermal substitute in order to delineate the amount of cellular recruitment, collagen deposition and neovascularization present compared with control wounds. The investigators hypothesize that OASIS® Ultra will provide a faster healing time as well as the re-establishment of a dermis for further skin graft application. The investigators anticipate that our study will define parameters for the application of OASIS® Ultra as well as potentially demonstrating the advantages in healing time, healed wound quality and hospital stay.
Interventions
- DEVICE OASIS Ultra
- DEVICE Wound VAC Standard Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2013-05 |
| Est. Completion | 2015-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01848821
The ClinicalTrials.gov registry entry for NCT01848821 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which OASIS Ultra is the first listed.
NCT01848821 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01848821 about?
NCT01848821 is a clinical study titled "The Effect of OASIS Ultra on Critical Sized Wound Healing". The aim of this study is to evaluate the speed and quality with which OASIS® Ultra (Healthpoint Biotherapeutics; Fort Worth, Texas) increases wound healing in the critical sized defect. The investigators intend on confirming the histological composition of the dermal substitute in order to delineate...
What is the current status of trial NCT01848821?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2013-05. Estimated completion is 2015-07.
What interventions are being tested in trial NCT01848821?
The interventions under investigation include: OASIS Ultra (DEVICE), Wound VAC Standard Therapy (DEVICE).
Who is sponsoring clinical trial NCT01848821?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.